2 Hrs
Source:
المشهد
Lilly drugs top 20% loss
Eli Lilly announced promising results for two obesity drugs at Obesity Week 2026, with average weight reductions exceeding 20% in two clinical trials. The combination “Elora T.Z.P.” reduced weight by 23.3% in adults with type 2 diabetes after 48 weeks, while Zepbound reduced body mass index by 21.4% in adolescents aged 12 to 18 after 72 weeks. Blood sugar levels also improved among the adult participants, and weight-related quality of life improved among the adolescents. The company has not yet released the full trial results.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)